Alzamend Neuro (ALZN) Expected to Announce Quarterly Earnings on Wednesday

Alzamend Neuro (NASDAQ:ALZN) is projected to issue its results before the market opens on Wednesday, September 10th. Analysts expect the company to announce earnings of ($3.69) per share for the quarter.

Alzamend Neuro Price Performance

Shares of ALZN stock opened at $2.36 on Tuesday. Alzamend Neuro has a 12-month low of $2.06 and a 12-month high of $20.25. The firm has a 50-day moving average price of $2.66 and a 200 day moving average price of $4.68.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ALZN. Ascendiant Capital Markets dropped their target price on shares of Alzamend Neuro from $180.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, August 21st. Wall Street Zen downgraded shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Alzamend Neuro currently has an average rating of “Buy” and an average price target of $45.00.

Insider Transactions at Alzamend Neuro

In related news, Director Milton C. Ault III sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, July 31st. The shares were sold at an average price of $2.22, for a total transaction of $222,000.00. Following the completion of the transaction, the director owned 8,260 shares in the company, valued at approximately $18,337.20. The trade was a 92.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 243,429 shares of company stock worth $627,895 in the last ninety days. 30.21% of the stock is currently owned by insiders.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.